Siemens AG

Siemens AG: Acquisition of Bayer Diagnostics - Medical Solutions Group further
expands position in key high-growth molecular diagnostics market

Siemens has signed an agreement with Bayer to acquire the chemical and
pharmaceutical company's Diagnostics Division. The acquisition will enable
Siemens Medical Solutions to expand its position in the high-growth molecular
diagnostics market. The purchase price for Bayer HealthCare Diagnostics - which
had sales of Euro 1.4 billion and a double-digit EBITDA margin in fiscal 2005 - is
roughly Euro 4.2 billion. This acquisition is subject to regulatory approvals.

With the acquisition Bayer Diagnostics Siemens consequently executes on its
strategy in the area of Healthcare. For the first time in the healthcare
industry an integrated diagnostics is being created company by combining the
entire imaging diagnostics, laboratory diagnostics and clinical IT value chain
under one roof.

This acquisition would make Siemens Medical Solutions No. 2 worldwide in
immunodiagnostics. In addition, this will enable the Siemens Group to tap the
rapidly growing market for molecular diagnostics based on gene analysis (nucleid
acid testing). Bayer Diagnostics is also a world market-leader in clinical
chemistry with a leading position in near-patient testing, laboratory automation
and hematology (blood cell diagnostics).

End of the ad-hoc announcement.

Contact: Siemens AG
         Irina Pchelova, +49 89 636-33693
         Fax: +49 89 636-32830
         Mobile: +49 175 5724998
         irina.pchelova@siemens.com
Siemens N Ord (LSE:SIE)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Siemens N Ord Charts.
Siemens N Ord (LSE:SIE)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Siemens N Ord Charts.